Sangui BioTech International Inc. Reports Earnings Results for the Fiscal Year 2017; Provides Revenue Guidance for the Full Calendar Year 2017
October 23, 2017 at 10:00 am EDT
Share
Sangui BioTech International Inc. reported earnings results for the fiscal year 2017. For the period, the company achieved revenues from royalty income and product sales of USD 67,653. In the same period of the previous year the comparable revenue amounted to USD 48,009. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2017 increased by 41% compared to previous year. After a strong year-end business in the second quarter, sales in the third and fourth quarters were also significantly higher than in the previous year's quarter. Operating loss decreased compared to the prior year by USD 44,105 to USD 316,799.
For the full calendar year 2017, however, the company is still expecting the increase in sales of Granulox and corresponding royalty revenues.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
